Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: oaktownaj who wrote (38448)	10/16/2000 9:32:13 AM
From: Rande Is	Read Replies (3) \| Respond to of 57584

AJ, check out reply # 37110. Inkine Pharmaceuticals. They make and have patented a salt tablet, to replace the sodium drinks one must take the day before a colonoscopy. And as anyone else over 40 can attest, a poke in the eye from a large stick is far more pleasant than drinking a purging product. Here is the part I liked best from their news: There was no significant difference in cleansing efficacy across the groups, and patients taking the sodium phosphate tablets experienced significantly less nausea, abdominal pain and bloating than those taking Colyte or Fleet. The news from September, which got many people looking more closely at this company: InKine/Sodium Phosphate Tablets-2:Pdt Well-Tolerated Dow Jones Newswires BLUE BELL, Pa. -- InKine Pharmaceutical Co.'s (INKP) sodium phosphate tablets proved safe and effective in study of 305 patients undergoing diagnostic colonoscopy. InKine makes Visicol, a patented version of the tablets. In a press release Wednesday, InKine said the results of the study will be published in the September issue of Gastrointestinal Endoscopy. The study compared sodium phosphate tablets to three traditional purge therapies: Colyte, Fleet and Phospho-Soda. Endoscopists evaluated the quality of bowel cleansing, while patients answered a questionnaire designed to analyze tolerability. There was no significant difference in cleansing efficacy across the groups, and patients taking the sodium phosphate tablets experienced significantly less nausea, abdominal pain and bloating than those taking Colyte or Fleet. This is hardly the only such product from this company. I like that they patented a salt tablet for this use. It is such a brilliant use that none of the other massive companies even thought of doing. Its along the lines of improving upon 'the wheel'. InKine Pharmaceutical Company, Inc. is a publicly traded biopharmaceutical company focused on the diagnosis and treatment of cancer and autoimmune diseases. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. Support of early-stage product opportunities comes through its university-based sponsored research agreements. InKine's portfolio includes two late-stage clinical compounds: Diacol, a tablet bowel cleansing product for procedures including colonoscopies undergoing FDA review, and CBP-1011, a steroid molecule in Phase III trials for the treatment of idiopathic ihrombocytopenic purpura and Phase II trials for the treatment of inflammatory bowel disease. In addition, the Company is developing preclinical compounds including Angiocidin, a potent and specific angiogenesis inhibitor for potential use in cancer patients I know that I will gladly take the tablets next time. Rande Is